Intravenous glial‐derived neurotrophic factor gene therapy of experimental Parkinson's disease with Trojan horse liposomes and a tyrosine hydroxylase promoter

Journal of Gene Medicine - Tập 10 Số 3 - Trang 306-315 - 2008
Chun‐Fang Xia1, Rubén J. Boado1, Yun Zhang1, Chun Chu1, William M. Pardridge2
1Department of Medicine, UCLA, Los Angeles, CA, USA
2UCLA Warren Hall 13‐164, 900 Veteran Avenue, Los Angeles, CA 90024, USA.

Tóm tắt

AbstractBackgroundRats with experimental Parkinson's disease (PD) are treated with intravenous glial‐derived neurotrophic factor (GDNF) plasmid DNA, non‐viral gene therapy using Trojan horse liposomes (THLs) targeted with a monoclonal antibody (MAb) to the rat transferrin receptor (TfR). Expression of the transgene is confined to catecholaminergic cells by placement of the GDNF gene under the influence of the rat tyrosine hydroxylase (TH) promoter.MethodsA 13‐kb eukaryotic expression plasmid, designated pTHpro‐GDNF, is engineered in which the human prepro GDNF cDNA is driven by 8 kb of the 5′‐flanking sequence of the rat TH promoter (pro), and is 3′‐flanked by the bovine growth hormone transcription termination sequence. The pTHpro‐GDNF plasmid DNA is encapsulated in THLs targeted with a TfRMAb, and a single intravenous injection is given to rats at 2 weeks after experimental PD is induced by intra‐cerebral 6‐hydroxydopamine.ResultsExpression of the GDNF gene, under the influence of the TH promoter, is restricted compared to GDNF expression under the influence of the cytomegalovirus promoter. GDNF is elevated only in organs of the rat where TH gene expression is observed, including the substantia nigra, liver and adrenal gland. The single, delayed intravenous administration of the GDNF gene therapy causes a lasting reduction in apormorphine‐induced rotation, which is correlated with a 19‐fold increase in striatal TH enzyme activity. Both dose‐response and time‐responses are observed.ConclusionsSustained therapeutic effects are achieved in experimental PD with a delayed single intravenous dosing of GDNF plasmid DNA gene therapy, using receptor‐targeted THLs and a region‐specific promoter. Copyright © 2007 John Wiley & Sons, Ltd.

Từ khóa


Tài liệu tham khảo

10.1126/science.8493557

10.1016/0304-3940(94)90218-6

10.1016/S0306-4522(97)83045-X

10.1016/S0304-3940(03)00007-7

10.1002/ana.20374

10.1126/science.290.5492.767

10.1006/exnr.2002.8006

10.1523/JNEUROSCI.4421-04.2005

10.1016/j.nbd.2005.06.015

10.1038/sj.gt.3302844

10.1016/S0076-6879(03)73032-8

10.1023/A:1010910523202

10.1073/pnas.221450098

10.1016/S1525-0016(02)00018-7

Zhang Y, 2003, Organ‐specific gene expression in the rhesus monkey eye following intravenous non‐viral gene transfer, Mol Vis, 9, 465

10.1002/jgm.575

10.1006/exnr.2001.7842

10.1002/jgm.1046

Pardridge WM, 2007, Gene Transfer: Delivery and Expression of DNA and RNA, 701

10.1089/10430340360464660

10.1016/S1385-299X(03)00023-0

10.1089/104303404322959498

10.1016/0896-6273(91)90061-4

10.1016/S0169-328X(02)00694-0

10.1016/0169-328X(94)90011-6

10.1016/j.bbrc.2003.11.029

10.1016/j.neulet.2007.06.041

10.1046/j.1471-4159.1998.71020478.x

West GJ, 1977, Adrenergic, cholinergic, and inactive human neuroblastoma cell lines with the action‐potential Na+ ionophore, Cancer Res, 37, 1372

10.1073/pnas.94.16.8818

10.1046/j.1460-9568.2003.02800.x

10.1111/j.1471-4159.2007.04856.x

10.1007/s11095-006-0274-x

10.1002/bit.21120

Thông tin
Thông tin xuất bản

Journal of Gene Medicine

Tập 10 Số 3

306-315

Thông tin tác giả